• First participants dosed in phase 1 study of nasal spray for treatment of MDD

    13 days ago - By Healio

    A biopharmaceutical company announced the first participants have been dosed in its phase 1 clinical trial of PH10, an investigational pherine nasal spray to treat major depressive disorder.
    According to a release from Vistagen, the objective of its planned single-center, randomized, double-blinded, placebo-controlled phase 1 study is to investigate the safety and tolerability of PH10 in 12 healthy adult subjects.
    The clinical trial is also intended to confirm the favorable safety profile of PH10 previously established in three prior clinical studies conducted in Mexico, including a published
    Read more ...

     

  • Psychedelic Succeeds as Quick Depression Fix in Early Trial

    Psychedelic Succeeds as Quick Depression Fix in Early Trial

    13 days ago - By MedPageToday

    An investigational N,N-dimethyltryptamine treatment - commonly known as the hallucinogen DMT - achieved the primary endpoint in a phase IIa trial for major depressive disorder , developer Small Pharma announced.
    Paired...
    Read more ...

     

  • DMT - the potent psychedelic in Ayahuasca - treats depression after a SINGLE dose

    DMT - the potent psychedelic in Ayahuasca - treats depression after a SINGLE dose

    13 days ago - By Daily Mail

    Up to six in ten who received a single dose of DMT intravenously before therapy were declared depression-free three months later, in a clinical trial by Canada-based Small Pharma.
    Read more ...